Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review

Obesity Research & Clinical Practice, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets

Nutrients, Год журнала: 2025, Номер 17(6), С. 965 - 965

Опубликована: Март 10, 2025

With the prevalence of obesity and overweight increasing at an alarming rate, more researchers are focused on identifying effective weight loss strategies. The ketogenic diet (KD), used as a treatment in epilepsy management for over 100 years, is additionally gaining popularity method. Although its efficacy well documented, areas where it may be beneficial to other dietary approaches need carefully examined. objective this paper identify potential benefits KD alternative strategies based comprehensive literature review. It has been shown that bioenergetically efficient than strategies, inter alia owing effect curtailing hunger, improving satiety decreasing appetite (influence hunger hormones sensation hunger), inducing faster initial (associated with lower glycogen levels reduced water retention), controlling glycaemia insulinemia (directly attributable low-carbohydrate nature indirectly described). These effects accompanied by improved insulin sensitivity, inflammation (through ketone bodies avoidance pro-inflammatory sugars), pharmacological control (the diet’s mechanisms similar those medication but without side effects), positive impacts psychological factors food addiction. Based authors’ review latest research, reasonable conclude that, due these many additional health benefits, advantageous diet-based This important hypothesis deserves further exploration, which could achieved including outcome measures future clinical trials, especially when comparing different diets equal caloric value.

Язык: Английский

---

Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma

Diabetes Metabolic Syndrome and Obesity, Год журнала: 2025, Номер Volume 18, С. 805 - 818

Опубликована: Март 1, 2025

Proteomics was used to study the effect of semaglutide on expression renal protein in obese mice, and looking for proteins that could improve prognosis Kidney Renal Clear Cell Carcinoma (KIRC). Thirty-six mice were randomly divided into normal-fat diet group (NFD), high-fat (HFD), plus intervention (HS). Collected serum, urine, kidney tissue samples, detected urinary protein/creatinine, blood glucose, lipid, inflammation, oxidative stress other related indicators. Different staining methods analyze pathological changes mice's kidneys. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis total kidneys mice. Finally, bioinformatics technology significantly different expressed (DEPs). The mechanism protecting phosphorylation, PPAR signaling pathway, thiamine, butyric acid tryptophan metabolism pathways. Moreover, increase Man1a1 Ntn4 while high-expression KIRC population had a better overall survival rate. Semaglutide regulate development by up-adjusting Ntn4.

Язык: Английский

---

Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients

Cancers, Год журнала: 2024, Номер 17(1), С. 78 - 78

Опубликована: Дек. 30, 2024

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management. This comprehensive study investigated the relationship between GLP-1RA use and cancer incidence individuals with across a 5-year follow-up period. Methods: We conducted large-scale cohort using TriNetX US Collaborative Network database (2013–2023) examining adult patients obesity. The utilized propensity score matching to pair GLP-1RA-treated controls (1:1) nearest neighbor method. Cancer served as primary outcome measure over follow-up, subgroup analyses considering individual agents, patient sex, BMI categories. Results: Analysis revealed cancer-risk reductions associated multiple types compared matched controls. Notable risk were observed gastrointestinal (HR 0.67, 95% CI 0.59–0.75), skin 0.62, 0.55–0.70), breast 0.72, 0.64–0.82), female genital 0.61, 0.53–0.71), prostate 0.68, 0.58–0.80), lymphoid/hematopoietic cancers 0.69, 0.60–0.80). Semaglutide superior protective effects, particularly 0.45, 0.37–0.53). Conversely, liraglutide showed increased risks thyroid 1.70, 1.03–2.82) respiratory 1.62, 1.13–2.32). Conclusions: research provides compelling evidence GLP-1RA’s potential role reduction, semaglutide showing promising results. differential effects among agents emphasize importance of personalized medicine approaches. These findings suggest implications clinical practice future both management prevention.

Язык: Английский

---

Finerenone and semaglutide: Role in heart failure with reduced ejection fraction

World Journal of Cardiology, Год журнала: 2025, Номер 17(5)

Опубликована: Май 23, 2025

Obesity and type 2 diabetes mellitus commonly coexist with heart failure (HF) may contribute to the pathogenesis of HF preserved ejection fraction. With progression in management therapies for fraction, mechanism behind beneficial actions finerenone semaglutide remains enigmatic. For decades, cardiorenal protective effects aldosterone blockage patients chronic kidney disease have been significant interest. But due multiple side effects, these trials were likely stop.

Язык: Английский

---

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m² in the phase 2 trial of survodutide, a glucagon/GLP‐1 receptor dual agonist

Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Abstract Aim To explore the effects of sex and baseline body mass index (BMI) on efficacy safety survodutide in people with a BMI ≥27 kg/m 2 . Materials Methods Totally 387 (aged 18–75 years, , without diabetes) were randomized 1:1:1:1:1 to once‐weekly subcutaneous (0.6, 2.4, 3.6 or 4.8 mg) placebo for 46 weeks (20‐week dose escalation; 26‐week maintenance). Participants categorized according BMI. Data analysed descriptively full analysis set (FAS), assigned at randomization (planned treatment) using on‐treatment data all censored COVID‐19‐related treatment discontinuations. ( ClinicalTrials.gov number: NCT04667377). Results After treatment, females had greater reductions bodyweight waist circumference than males. lower proportional those higher BMI; trend was reversed circumference. Rates adverse events (AEs) comparable between subgroups Nausea most frequently reported gastrointestinal AE subgroups. Conclusions In associated clinically meaningful when compared placebo, prespecified based BMI, tolerated doses tested.

Язык: Английский

---

Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease

Annals of Pharmacotherapy, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

Objective: To summarize the current knowledge on therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using search terms , MASLD NAFLD nonalcoholic fatty treatment and therapy PubMed (from January 1, 2019, through February 2025), National Institutes Health (NIH) Scopus World Organization (WHO) data. Study Selection Extraction: All relevant clinical trials, articles, package inserts, guidelines evaluating clinically evidence regarding were considered for inclusion. Synthesis: RAs have shown promising results treatment. Semaglutide has demonstrated efficacy reducing fat content, inflammation, fibrosis, with trials indicating improvements hepatic biomarkers cardiometabolic risk factors. Similarly, tirzepatide been substantial weight loss significant reductions fibrosis markers. Both agents exert their effects mechanisms involving improved insulin sensitivity, reduced lipid accumulation, attenuation inflammation. Relevance to Patient Care Clinical Practice: Given high prevalence patients obesity type 2 diabetes, semaglutide could play a critical role practice by addressing multiple facets disease. fat, improving biomarkers, mitigating risks, which are leading causes morbidity mortality patients. Incorporating these therapies into significantly enhance patient outcomes targeting both liver-related systemic complications Conclusions: GLP1 show great promoting loss, glycemic control,

Язык: Английский

---

Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS)

Indus journal of bioscience research., Год журнала: 2025, Номер 3(3), С. 238 - 243

Опубликована: Март 18, 2025

Background: This study compares the effectiveness of metformin (MET) monotherapy versus a combination MET and liraglutide (LIRA) in managing metabolic syndrome overweight women with polycystic ovary (PCOS), focusing on weight reduction body mass index (BMI). Methods: A prospective cohort was conducted at Lady Dufferin Hospital, Karachi from April 2024 to Oct 2024, involving 70 aged 18–40 years, diagnosed PCOS based Rotterdam criteria, having BMI ≥ 27.5 kg/m². Participants were randomly assigned into two groups: Group received (1500 mg/day), B mg/day) plus LIRA (1.2 for 12 weeks. Baseline post-treatment outcomes, including weight, BMI, waist circumference, lipid profiles, analyzed. Results: Both treatment regimens significantly improved parameters. demonstrated superior results an average loss 10.30 ± 1.30 kg 3.72 0.67, compared A’s 5.99 2.87 2.24 1.07 (p < 0.001). Improvements triglyceride levels, HDL cholesterol, circumference more pronounced B. However, no significant changes hypertension parameters observed either group. Conclusion: The is effective than patients. dual therapy offers enhanced benefits, potentially improving both reproductive overall health. Further long-term, multicenter studies are warranted explore its broader impacts sustainability.

Язык: Английский

---

Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats: Contribution of cAMP/PKA/p-CREB and M1/M2 Microglia Polarization

Journal of Neuroimmune Pharmacology, Год журнала: 2025, Номер 20(1)

Опубликована: Апрель 16, 2025

Abstract Fibromyalgia (FM) is a pain disorder characterized by pervasive musculoskeletal associated with exhaustion, depression, and irregular sleep patterns. Semaglutide, an innovative glucagon-like peptide-1 (GLP-1) agonist, has shown analgesic effects modulating hypersensitivity in animal models of inflammatory pain. The objective this study to ascertain semaglutide's therapeutic potential against FM-like symptoms caused reserpine. Reserpine (1 mg/kg/day; SC) was administered into rats for 3 consecutive days, then they were treated daily semaglutide intraperitoneally low (5 nmol/kg), intermediate (10 or high doses (20 respectively, 14 days. Semaglutide alleviated reserpine induced histopathological immunohistopathological changes spinal cord evidenced remarkable rise immuno-expression cluster differentiation 163 (CD163) contrary significant diminution CD86 level as compared group. also had effect improved motor incoordination, depression brought on Furthermore, it anti-inflammatory impact via stimulating cyclic adenosine monophosphate (cAMP)/ protein kinase A (PKA)/ cAMP response element (CRE)-binding (CREB) signaling pathway shifting M1/M2 macrophage polarization towards the M2. Semaglutide's actions manifested through inhibition inducible nitric oxide synthase reduction dorsal root ganglia concentrations tumor necrosis factor-α together elevation levels arginase-1 interleukin-4. Graphical

Язык: Английский

---

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review

Diseases, Год журнала: 2025, Номер 13(5), С. 129 - 129

Опубликована: Апрель 22, 2025

Obesity is a growing global health challenge, necessitating effective treatment options beyond lifestyle interventions. This narrative review explores established and emerging pharmacotherapies for weight management, including parenteral agents like Liraglutide, Semaglutide, Setmelanotide, Tirzepatide, as well peroral medications such Phentermine, Phentermine/Topiramate, Bupropion/Naltrexone, Orlistat, Metformin. Newer treatments Cagrilintide Bimagrumab show promise enhancing loss outcomes. Parenteral GLP-1 receptor agonists demonstrate superior efficacy compared to traditional medications, with gastrointestinal side effects being the most common. Artificial intelligence presents intriguing opportunities enhance strategies; however, its integration into clinical practice remains investigational requires rigorous validation. While current anti-obesity deliver significant benefits, future research must determine efficacy, safety, cost-effectiveness of AI-driven approaches. includes exploring how AI can complement combination therapies tailor personalized interventions, thereby grounding potential benefits in robust evidence. Future directions will focus on integrating trials refine personalize obesity management strategies.

Язык: Английский

---